CASI Pharmaceuticals annual current ratio
2021
2022
2023
2024
2025
CASI Pharmaceuticals Current Ratio Growth & History (CASIF)
CASI Pharmaceuticals's current ratio was 0.27 for fiscal 2025.
View full CASI Pharmaceuticals company overviewCASI Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.27 | −0.81 | −75.05% |
| 2024 | 2024-12-31 | 1.09 | −2.46 | −69.40% |
| 2023 | 2023-12-31 | 3.55 | −0.77 | −17.83% |
| 2022 | 2022-12-31 | 4.32 | −0.38 | −8.13% |
| 2021 | 2021-12-31 | 4.70 | — | — |
CASI Pharmaceuticals quarterly current ratio
Q4.21
Q4.22
Q4.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.15 | −0.33 | −68.74% |
| Q4 2025 | 2025-12-31 | 0.27 | −0.81 | −75.05% |
| Q3 2025 | 2025-09-30 | 0.30 | — | — |
| Q2 2025 | 2025-06-30 | 0.48 | — | — |
| Q1 2025 | 2025-03-31 | 0.81 | — | — |
| Q4 2024 | 2024-12-31 | 1.09 | −2.46 | −69.40% |
| Q4 2023 | 2023-12-31 | 3.55 | −0.77 | −17.83% |
| Q4 2022 | 2022-12-31 | 4.32 | −0.38 | −8.13% |
| Q4 2021 | 2021-12-31 | 4.70 | — | — |
CASI Pharmaceuticals current ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, CASI Pharmaceuticals's current ratio decreased from 4.70 to 0.27, a change of −4.43. The latest reported quarter, Q2 2026, shows 0.15.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CASI Pharmaceuticals source filings ↗